| Drug / Therapy | orforglipron |
| Indication | obesity oral GLP-1 |
| Decision Type | PDUFA |
| Conditions | obesity oral GLP-1 |
| Interventions | orforglipron |
Eli Lilly and Company (LLY) operates in the Diabetes/Oncology sector. The current BTS Score is 43 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for orforglipron by Eli Lilly and Company (LLY) is scheduled for November 15, 2026. This is the target date for the FDA to make a decision on this application.
orforglipron is being developed by Eli Lilly and Company for the treatment of obesity oral GLP-1. It is under FDA review.
If orforglipron receives FDA approval, Eli Lilly and Company (LLY) would be able to market the drug in the United States for obesity oral GLP-1. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for LLY on DilutionWatch at dilutionwatch.com/stock/LLY.html.
You can view the full BiotechSign company profile for Eli Lilly and Company (LLY) at biotechsign.com/app/company/LLY, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.